Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Business
Exelixis, Bms in R&D Pact
December 12, 2005
| A version of this story appeared in
Volume 83, Issue 50
Exelixis and Bristol-Myers Squibb are collaborating on therapies targeting the Liver X Receptor (LXR), a nuclear hormone receptor implicated in cardiovascular and metabolic disorders. Exelixis, a nuclear receptor specialist, has identified a series of LXR agonist drug candidates. Under the deal, BMS will undertake preclinical and clinical development as well as the manufacture and sale of any new drug. It will pay Exelixis $17.5 million up front, $10 million annually for two years, and milestone payments that could total $140 million.
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter